Cardiology Search
Cardiology Cardiology
myocardial%20infarction%20w_%20st-segment%20elevation
MYOCARDIAL INFARCTION W/ ST-SEGMENT ELEVATION
Myocardial infarction is death of cardiac myocytes (necrosis) caused by prolonged ischemia. The term acute "usually" refers to the time 6 hours to 7 days following pathologic appearance of the infarct.
The patient may experience ischemic-type chest discomfort with accompanying symptoms of nausea, vomiting, dyspnea, diaphoresis, lightheadedness, dizziness, syncope, fatigue and weakness.
Rapid diagnosis and risk stratification of chest pain in patients are important to identify acute myocardial infarction patients who will benefit from reperfusion therapy.

Myocardial Infarction w/ ST-Segment Elevation Drug Information

Drug Information

Indication: 60 mg: Co-administered w/ acetylsalicylic acid (ASA) for prevention of atherothrombotic events in adult patien...

Indication: Substitution treatment of essential HTN &/or stable CAD in patients already controlled w/ perindopril &...

Indication: HTN. Stable CAD: Risk reduction of cardiac events in patients w/ history of MI &/or revascularisation. 5 m...

Indication: Essential HTN.

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Essential HTN.

Indication: Thrombolytic treatment in acute MI, acute massive pulmonary embolism w/ haemodynamic instability & of acut...

Indication: Thrombolytic treatment of acute MI. Treatment initiated as soon as possible after symptom onset.

Indication: Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing majo...

Indication: Essential HTN when BP is inadequately controlled by monotherapy w/ telmisartan.

1  /  13
1  /  13
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Finerenone reduces CKD progression, CV risk
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.